Investigation the role of Human Leukocyte Antigen-G in Iraqi patients with papillary thyroid carcinoma
Main Article Content
Abstract
Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex (MHC) protein with well-known immunomodulatory characteristics. It is also believed to be an important sign of immune tolerance in cancer cells. Immune Escape. HLA-G is also associated with disease development and prognosis in cancer patients. The goal of this study was to compare soluble HLA-G (sHLA-G) levels before and after radioactive iodine therapy (RAI) by enzyme immunoassay (ELISA). Immunohistochemistry was used to examine HLA-G protein expression in thyroid tissues from patients with papillary thyroid cancer (PTC) to investigate the relationship between HLA-G expression and patients' clinical variables. Prospective research included 138 blood samples from patients and controls, as well as 25 thyroid paraffin-embedded tissues from individuals suffering from papillary thyroid cancer (PTC) and controls. Our findings demonstrated a significant difference in the means of people who had radioactive iodine therapy against those who did not (Mean SE = 4.19 0.31, 2.216 0.08, respectively). HLA-G staining, on the other hand, was identified in tumor cells in papillary thyroid cancer, all sections were positive, strongly stained and completely membranous, indicating the presence of HLA-G protein in the tested material. These findings suggest that HLA-G may be involved in the pathogenesis of papillary thyroid cancer.
Received 05/03/2023
Revised 18/06/2023
Accepted 20/06/2023
Published Online First 20/11/2023
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Nunes LM, Ayres FM, Francescantonio IC, Saddi VA, Avelino MA, Alencar RD, et al. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer. Hum Immunol. 2013;74 (4): 447-51. https://doi.org/10.1016/j.humimm.2012.12.012.
Siraj AK, Parvathareddy SK, Qadri Z, Siddiqui K, Al-Sobhi SS, Al-Dayel F, et al. Annual hazard rate of recurrence in Middle Eastern papillary thyroid cancer over a long-term follow-up. Cancers. 2020; 12(12): 3624. https://doi.org/10.3390/cancers12123624.
American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017; 123(3): 372-81. https://doi.org/10.1002/cncr.30360.
Shih IM. Application of HLA-G expression in the diagnosis of human cancer. Hum Immunol 2007; 68(4): 272–6. https://doi.org/10.1016/j.humimm.2007.01.010.
Rebmann, V, LeMaoult, J, Rouas-Freiss, N, Carosella ED, Grosse-Wilde H. Report of the wet workshop for quantification of soluble HLA-G in Essen. Hum Immunol. 2005; 66(8), 853-863. https://doi.org/10.1016/j.humimm.2005.05.003.
Davies B, Hiby S, Gardner L, Loke YW, King A. HLA‐G expression by tumors. Am J Reprod Immunol. 2001; 45(2): 103-7. https://doi.org/10.1111/j.8755-8920.2001.450207.
Shams AA, Hamssa AJ. Relationship between rs1800796 Polymorphism of IL-6 Gene and IL-6 Serum Level with Thyroid Hormones in a Sample of Iraqi Celiac Disease Patients. Iraqi J Sci. 2022; 21(2).
Kaliszewski K, Diakowska D, Rzeszutko M, Rudnicki, J. Obesity and overweight are associated with minimal extrathyroidal extension, multifocality and bilaterality of papillary thyroid cancer. J Clin Med. 2021; 10 (5): 970. https://doi.org/https://doi.org/10.3390/jcm10050970.
Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr. -Relat. Cancer. 2014; 21(5): T273-T283. https://doi.org/10.1530/ERC-14-0053.
Cho YA, Kim J. Thyroid cancer risk and smoking status: a meta-analysis. Cancer Causes Control. 2014; 25, 1187-1195. https://doi.org/10.1007/s10552-014-0422-2.
Kunzmann AT, Coleman HG, Huang WY, Berndt SI. The association of lifetime alcohol use with mortality and cancer risk in older adults: A cohort study. PLoS Med. 2018; 15(6): e1002585. https://doi.org/10.1371/journal.pmed.1002585.
Mousa SA, Hercbergs A, Lin HY, Keating KA, Davis PJ. Actions of thyroid hormones on thyroid cancers. Front Endocrinol. 2021; 12: 691736. https://doi.org/10.3389/fendo.2021.691736.
Rummel SK, Ellsworth RE. The role of the blood ABO group in cancer. Future Sci. 2016; 2(2). https://doi.org/10.4155/fsoa-2015-0012.
Ito N, Yokota M., Nagaike C, Morimura Y, Hatake K, Tanaka O, et al. Simultaneous expression of keratan sulphate epitope (a sulphated Poly-N-acetyllactosamine) and blood group ABH antigens in papillary carcinomas of the human thyroid gland. J Histochem. 1996; 28: 613-23. https://doi.org/10.1016/S0002-9440(10)63642-5.
Geneş D, Pekkolay Z, Şimşek M, Saraçoğlu H, Turgut M, Tuzcu AK. Importance and Risk Prediction of ABO Blood Group and Rh Factor in Papillary Thyroid Cancer. J Endocrinol. 2022; 4(1): 8-13. https://doi.org/10.30564/jer.v4i1.4133.
Khoshsirat S, Peyvandi AA, Oroei M, Peyvandi H, Rezaeifard A. The Estimation of Thyroid Cancer Risk based on Type 2 Diabetes Mellitus and ABO Blood Group. Turk J Oncol. 2019; 35(1). https://doi.org/10.5505/tjo.2020.2066.
Crescenzi A, Taccogna S, Turrini L, Modica DC, Papini E, Gallo A, et al. Phenotypic changes of the thyrocyte membrane in papillary thyroid carcinoma. A three-dimensional study. J Endocrinol Invest. 2011; 34: e64-e69. https://doi.org/10.1007/BF03347078.
Berta E, Lengyel I, Halmi S, Zrínyi M, Erdei A, Harangi M. Hypertension in thyroid disorders. Front Endocrinol. 2019; 10: 482. https://doi.org/10.3389/fendo.2019.00482.
Sharma AK, Arya R, Mehta R, Sharma R. Hypothyroidism and cardiovascular disease: factors, mechanism and future perspectives. Curr Med Chem. 2013; 20(35): 4411-8. https://doi.org/10.2174/09298673113206660255.
Wu P. Thyroid disorders and diabetes. It is common for a person to be affected by both thyroid disease and diabetes. Diabetes Self Manag. 2007; 24(5): 80-7.
Siraj S, Masoodi T, Siraj AK, Azam S, Qadri Z, Parvathareddy SK, et al. APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma. Cancers. 2022; 14(6): 1584. https://doi.org/10.3390/cancers14061584.
Marti JL, Morris LG, Ho AS. Selective use of radioactive iodine (RAI) in thyroid cancer: no longer “one size fits all”. Eur J Surg Oncol. 2018; 44(3): 348-56. https://doi.org/10.1016/j.ejso.2017.04.002.
Davies B, Hiby S, Gardner L, Loke YW, King A. HLA-G expression by tumors. Am J Reprod Immunol 2001; 45: 103–7. https://doi.org/10.1111/j.8755-8920.2001.450207.x.
Mwafaq K, Abbas K, Abdullah H, Ghafour A. The Immunohistochemically Estimation of CD63 in Iraqi Patients with Gastric Cancer. Baghdad Sci. J..2022; 19(5),0932-0932. https://doi.org/10.21123/bsj.2022.6272.
Ismael, K. The prognostic value of some epithelial-mesenchymal transition markers and metastasis-related markers in human transitional cell carcinoma of the bladder. Baghdad Sci. J. 2018; 15(3), 0244-0244. https://doi.org/10.21123/bsj.2018.15.3.0244.